|
Video: What is a Stock Split?
|
|
ENDRA Life Sciences is engaged in developing technology in clinical diagnostic ultrasound for patient access to the diagnosis and treatment of various medical conditions. Co.'s Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology uses a pulsed energy source, radio-frequency, to generate ultrasonic waves in tissue. These waves are then detected with ultrasound equipment and used to create images and other forms of data using its proprietary algorithms. Co. is also developing TAEUS for incorporation into new ultrasound systems manufactured by companies such as General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center. According to our NDRA split history records, ENDRA Life Sciences has had 1 split. | |
|
ENDRA Life Sciences (NDRA) has 1 split in our NDRA split history database. The split for NDRA took place on December 09, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of NDRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as ENDRA Life Sciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NDRA split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ENDRA Life Sciences shares, starting with a $10,000 purchase of NDRA, presented on a split-history-adjusted basis factoring in the complete NDRA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/11/2017 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$74.20 |
|
End price/share: |
$0.58 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.22% |
|
Average Annual Total Return: |
-51.43% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$78.18 |
|
Years: |
6.72 |
|
|
|
Date |
Ratio |
12/09/2022 | 1 for 20 |
|
|